Home › Chronic Lymphocytic Leukemia › Tennessee › Chattanooga
Chronic Lymphocytic Leukemia clinical trials in Chattanooga, TN
3 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Chattanooga (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RecruitingPhase 3
- Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Tennesse Oncology Chattanooga Downtown, Chattanooga
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RecruitingPhase 3
- Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH29 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA21 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI14 studies
- Chicago, IL14 studies
- Cincinnati, OH14 studies
Other studies in Chattanooga
- Non-Small Cell Lung Cancer11 studies
- Metastatic Cancer6 studies
- Myasthenia Gravis6 studies
- Ovarian Cancer5 studies
- Diabetes4 studies
- Lung Cancer4 studies
- Colorectal Cancer4 studies
- Chronic Kidney Disease4 studies
- Ischemic Stroke4 studies
- Steatotic Liver Disease4 studies
- Melanoma4 studies
- Cardiovascular Disease3 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.